Companies › BioGenCell
1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BGC101 (autologous EnEPC preparation) Autologous cell therapy containing endothelial progenitor cells (EnEPCs) and hematopoietic | – | Phase 1 | Chronic Limb-Threatening Ischemia | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02805023 | BGC101 (autologous EnEPC preparation) | Phase 1 | Chronic Limb-Threatening Ischemia | Cardiovascular | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.